Subsequent events (Details Narrative) - Subsequent Event [Member] - Chemomab Therapeutics Ltd [Member] - USD ($) $ in Millions |
1 Months Ended | 3 Months Ended | |
|---|---|---|---|
Jul. 07, 2026 |
Sep. 30, 2026 |
Sep. 30, 2026 |
|
| Subsequent Event [Line Items] | |||
| Gross proceeds | $ 30 | ||
| Pre-funded Warrants [Member] | |||
| Subsequent Event [Line Items] | |||
| Number of shares issued | 62,771,680 | ||
| Number of ADSs issued | 784,646 | ||
| Restricted Stock Units (RSUs) [Member] | |||
| Subsequent Event [Line Items] | |||
| Number of shares issued | 1,468,920 | ||
| Number of ADSs issued | 18,361 | ||
| Combined Company [Member] | Scipher Securityholders [Member] | |||
| Subsequent Event [Line Items] | |||
| Ownership percentage | 68.00% | ||
| Combined Company [Member] | Chemomab Securityholders [Member] | |||
| Subsequent Event [Line Items] | |||
| Ownership percentage | 32.00% |
| X | ||||||||||
- Definition Stock issued during period american. No definition available.
|
| X | ||||||||||
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets. No definition available.
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|